Recombinant human soluble thrombomodulin attenuates FK506-induced endothelial dysfunction through prevention of Akt inactivation
- 1 April 2014
- journal article
- research article
- Published by Elsevier in Experimental Cell Research
- Vol. 323 (1) , 112-117
Abstract
No abstract availableKeywords
Funding Information
- KAKENHI (24790985)
This publication has 14 references indexed in Scilit:
- FK506 induces endothelial dysfunction through attenuation of Akt and ERK1/2 independently of calcineurin inhibition and the caspase pathwayCellular Signalling, 2013
- Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation–associated thrombotic microangiopathyBlood, 2011
- Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammationJournal of Thrombosis and Haemostasis, 2011
- Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trialJournal of Thrombosis and Haemostasis, 2006
- The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanismJournal of Clinical Investigation, 2005
- Release of chromatin protein HMGB1 by necrotic cells triggers inflammationNature, 2002
- MAPK signal pathways in the regulation of cell proliferation in mammalian cellsCell Research, 2002
- Cellular survival: a play in three AktsGenes & Development, 1999
- Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantationBone Marrow Transplantation, 1998
- Antithrombotic effect of recombinant human thrombomodulin on thrombin- induced thromboembolism in miceBlood, 1990